

## COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

## RECENT NEWS

### [Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer](#)

Jan 15 2026, 8:45 AM EST

### [Propanc Biopharma Provides Shareholder Update](#)

Jan 13 2026, 8:45 AM EST

### [Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal](#)

Dec 22 2025, 7:00 AM EST

## STOCK OVERVIEW

Symbol	PPCB
Exchange	Nasdaq
Market Cap	4.19m
Last Price	\$0.3135
52-Week Range	\$0.303 - \$145.46

01/16/2026 08:58 PM EST

## INVESTOR RELATIONS

Propanc Biopharma, Inc.  
T: +61-03-9882-6723

[irteam@propanc.com](mailto:irteam@propanc.com)

## MANAGEMENT TEAM

### **James Nathanielsz**

CEO and Executive Chairman

### **Dr. Julian Kenyon, M.D.**

Chief Scientific Officer

### **Professor Klaus Kutz, M.D.**

Chief Medical Officer

### **Jeannine Zimmerman**

Chief Financial Officer

## PROPANC BIOPHARMA, INC.

302/6 Butler Street

Camberwell, VIC 3124

AU

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.